Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Mikkel Højlund & Christoph U. Correll. (2023) Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opinion on Pharmacotherapy 24:13, pages 1463-1489.
Read now
Read now
Renato de Filippis, Pasquale De Fazio, Raffaele Gaetano, Luca Steardo, Clemente Cedro, Antonio Bruno, Rocco Antonio Zoccali & Maria Rosaria Anna Muscatello. (2021) Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opinion on Drug Safety 20:7, pages 771-790.
Read now
Read now
Clifton Blackwood, Panna Sanga, Isaac Nuamah, Alexander Keenan, Arun Singh, Maju Mathews & Srihari Gopal. (2020) Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire. Patient Preference and Adherence 14, pages 1093-1102.
Read now
Read now
Tianmei Si, Jianmin Zhuo, Yu Feng, Huafei Lu, Di Hong & Lili Zhang. (2019) Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1685-1694.
Read now
Read now
Lyang Huh & Bong Ju Lee. (2019) Comparison of long-term efficacy and safety of blonanserin treatment in individuals with first-episode and relapsed schizophrenia: a 3-year retrospective study. Psychiatry and Clinical Psychopharmacology 29:4, pages 399-406.
Read now
Read now
Dominic Pilon, Tony B. Amos, Rhiannon Kamstra, Ameur M. Manceur, Antoine C. El Khoury & Patrick Lefebvre. (2019) Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. Current Medical Research and Opinion 35:1, pages 41-49.
Read now
Read now
David M. Taylor, Sitaram Velaga & Ursula Werneke. (2018) Reducing the stigma of long acting injectable antipsychotics – current concepts and future developments. Nordic Journal of Psychiatry 72:sup1, pages S36-S39.
Read now
Read now
Jingping Zhao, Lehua Li, Jianguo Shi, Yi Li, Xiufeng Xu, Keqing Li, Lili Zhang, Shangli Cai, Yu Feng, Jianmin Zhuo, Weihong Liu & Huafei Lu. (2017) Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study. Neuropsychiatric Disease and Treatment 13, pages 2045-2056.
Read now
Read now
Andrea de Bartolomeis, Andrea Fagiolini, Marco Vaggi & Claudio Vampini. (2016) Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. Neuropsychiatric Disease and Treatment 12, pages 99-108.
Read now
Read now
L. Orsolini, C. Tomasetti, A. Valchera, R. Vecchiotti, I. Matarazzo, F. Vellante, F. Iasevoli, E. F. Buonaguro, M. Fornaro, A. L. C. Fiengo, G. Martinotti, M. Mazza, G. Perna, A. Carano, A. De Bartolomeis, M. Di Giannantonio & D. De Berardis. (2016) An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety 15:10, pages 1329-1347.
Read now
Read now
Fan Zhang, Tianmei Si, Chiun-Fang Chiou, Anthony WF Harris, Chang Yoon Kim, Padmashree Jahagirdar & Steve Ascher. (2015) Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatric Disease and Treatment 11, pages 657-668.
Read now
Read now
Nesrin Dilbaz. (2015) New Targets for the Management of Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25:4, pages 407-428.
Read now
Read now
Srihari Gopal, An Vermeulen, Partha Nandy, Paulien Ravenstijn, Isaac Nuamah, José Antonio Buron Vidal, Joris Berwaerts, Adam Savitz, David Hough & Mahesh N. Samtani. (2015) Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Current Medical Research and Opinion 31:11, pages 2043-2054.
Read now
Read now
Luis San, Manuel Serrano, Fernando Cañas, Samuel Leopoldo Romero, Ángeles Sánchez-Cabezudo & Mariano Villar. (2015) Towards a pragmatic and operational definition of relapse in schizophrenia: A Delphi consensus approach. International Journal of Psychiatry in Clinical Practice 19:2, pages 90-98.
Read now
Read now
Istvan M. Majer, Fiona Gaughran, Christophe Sapin, Maud Beillat & Maarten Treur. (2015) Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. Journal of Market Access & Health Policy 3:1.
Read now
Read now
Stefania Ruiu, Maria Antonietta Casu, Gianluca Casu, Sara Piras & Giorgio Marchese. (2012) Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals. Expert Opinion on Pharmacotherapy 13:11, pages 1631-1643.
Read now
Read now
Articles from other publishers (47)
Kyle A. McKee, Candice E. Crocker, Katerina Dikaios, Nicola Otter, Andrea Bardell, Marc-André Roy, Amal Abdel-Baki, Lena Palaniyappan, Ashok Malla & Philip G. Tibbo. (2023) Short communication: Prevalence of long-acting injectable antipsychotic use in Canadian early intervention services for psychosis. Journal of Psychiatric Research 165, pages 77-82.
Crossref
Crossref
Giuseppe Cicala, Renato de Filippis, Maria Antonietta Barbieri, Paola Maria Cutroneo, Pasquale De Fazio, Georgios Schoretsanitis & Edoardo Spina. (2023) Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database. Frontiers in Psychiatry 14.
Crossref
Crossref
Hongyu Zheng, Xiaolu Jiang, Rong Yang, Shuo Wang & Hui Zhong. (2023) Changes in major psychiatric disorders in children and adolescents from 2001 to 2020: A retrospective single-center study. Frontiers in Psychiatry 13.
Crossref
Crossref
Mark Taylor, Dante Dangelo-Kemp, Dennis Liu, Steve Kisely, Simon Graham, Jodie Hartmann & Sam Colman. (2021) Antipsychotic utilisation and persistence in Australia: A nationwide 5-year study. Australian & New Zealand Journal of Psychiatry 56:9, pages 1155-1163.
Crossref
Crossref
Ofer Agid, Gary Remington, Carmen Fung, Natalie M. Nightingale, Marc Duclos & Gregory J. Anger. (2021) Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study. The Canadian Journal of Psychiatry 67:3, pages 226-234.
Crossref
Crossref
Azizah Attard, John Wakelam, Josephine Broyd, David Taylor & Jonathan Hafferty. (2022) Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital. Therapeutic Advances in Psychopharmacology 12, pages 204512532211130.
Crossref
Crossref
Ching-Hua Lin, Hung-Yu Chan, Fu-Chiang Wang & Chun-Chi Hsu. (2022) Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics. Therapeutic Advances in Psychopharmacology 12, pages 204512532210791.
Crossref
Crossref
Marjanne A. Piena, Natalie Houwing, Carla W. Kraan, Xiaofeng Wang, Heidi Waters, Ruth A. Duffy, Suresh Mallikaarjun & Craig Bennison. (2021) An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia. PharmacoEconomics 40:1, pages 121-131.
Crossref
Crossref
Edoardo G. Ostinelli, Simone Cavallotti, Valentina Fanti, Benedetta Demartini, Orsola Gambini & Armando D'Agostino. (2019) The reMAP project: A retrospective, 15‐year register study on inpatient care for youth with mental disorders. Early Intervention in Psychiatry 14:6, pages 705-713.
Crossref
Crossref
Harshita Gupta, Rutu Panchal, Niyati Acharya & Priti Jignesh Mehta. (2020) Controlled Parenteral Formulations: An Efficacious and Favourable Way to Deliver the Anti-psychotic Drugs. Current Psychiatry Research and Reviews 16:1, pages 42-59.
Crossref
Crossref
Lennart Kyllesø, Robert Løvsletten Smith, Øystein Karlstad, Ole A. Andreassen & Espen Molden. (2020) Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine. npj Schizophrenia 6:1.
Crossref
Crossref
Delbert G. RobinsonAnant SubramaniamPaul J. FearisRichard ShiMegan WalshLauren A. HannaJohn M. Kane. (2020) Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics. Psychiatric Services 71:4, pages 337-342.
Crossref
Crossref
Corrado Barbui, Federico Bertolini, Francesco Bartoli, Carmela Calandra, Camilla Callegari, Giuseppe Carrà, Armando D’Agostino, Claudio Lucii, Giovanni Martinotti, Daniele Mastromo, Daniele Moretti, Emiliano Monzani, Matteo Porcellana, Davide Prestia & Giovanni Ostuzzi. (2020) Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study. Therapeutic Advances in Psychopharmacology 10, pages 204512532097810.
Crossref
Crossref
Adam J. Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews & Bernardo Soares. (2019) Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies. Brazilian Journal of Psychiatry 41:6, pages 499-510.
Crossref
Crossref
Daniela PetrićValentino RačkiNadija GačoAna KaštelanMirjana Graovac. (2019) Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. Journal of Child and Adolescent Psychopharmacology 29:3, pages 197-204.
Crossref
Crossref
KyuYoung Lee. (2019) The Long-Acting Injectable Antipsychotics in Clinical Practice. Journal of Korean Neuropsychiatric Association 58:1, pages 29.
Crossref
Crossref
Tianmei Si, Nan Li, Huafei Lu, Shangli Cai, Jianmin Zhuo, Christoph U Correll, Lili Zhang & Yu Feng. (2018) Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. Journal of Psychopharmacology 32:6, pages 691-701.
Crossref
Crossref
Jonathan M. Meyer. (2018) Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectrums 22:S1, pages 14-28.
Crossref
Crossref
Lindah Cahling, Anders Berntsson, Gabriella Bröms & Lars Öhrmalm. (2018) Perceptions and knowledge of antipsychotics among mental health professionals and patients. BJPsych Bulletin 41:5, pages 254-259.
Crossref
Crossref
Björn M. Nilsson, Oscar Edström, Leif Lindström, Petter Wernegren & Robert Bodén. (2017) Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections. International Clinical Psychopharmacology 32:4, pages 219-224.
Crossref
Crossref
Laura G. Leahy. (2017) From Immediate Release to Long Acting Drug Delivery Systems: What Do They Mean and Why Do They Matter?. Journal of Psychosocial Nursing and Mental Health Services 55:5, pages 19-23.
Crossref
Crossref
Yueren Zhao, Tetsuya Tanioka, Yuko Yasuhara, Kensaku Takase, Soji Tsuboi, Kiyoshi Fujita, Rozzano C. Locsin & Nakao Iwata. (2017) Effects of Depth of Needle Insertion with Risperidone Long-Acting Injectable in Persons with Schizophrenia: A Randomized Double-Blind Study. Open Journal of Psychiatry 07:04, pages 374-385.
Crossref
Crossref
Yuko YASUHARA, Tetsuya TANIOKA, Kensaku TAKASE, Yueren ZHAO, Kazushi MOTOKI & Takaharu AZEKAWA. (2017) Evaluations of muscle echogenicities in patients treated with second generation long acting injectable antipsychotics. Neurosonology 30:1, pages 13-17.
Crossref
Crossref
Steven D. Targum, Robert Risinger, Yangchun Du, J. Cara Pendergrass, Hassan H. Jamal & Bernard. L. Silverman. (2017) Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. Schizophrenia Research 179, pages 64-69.
Crossref
Crossref
Fabienne Chou, Earle Reome & Patricia Davis. (2016) Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder. Mental Health Clinician 6:5, pages 254-259.
Crossref
Crossref
S. Breit & G. Hasler. (2015) Chancen und Kontroversen von Depotantipsychotika in der Behandlung von Patienten mit SchizophrenieAdvantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia. Der Nervenarzt 87:7, pages 719-723.
Crossref
Crossref
Stephanie Sampson, Prakash Hosalli, Vivek A Furtado & John M Davis. (2016) Risperidone (depot) for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Stefaan Rossenu, Adriaan Cleton, David Hough, Herta Crauwels, An Vandebosch, Joris Berwaerts, Marielle Eerdekens, Virginie Herben, Marc De Meulder, Bart Remmerie & Igor Francetic. (2015) Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Clinical Pharmacology in Drug Development 4:4, pages 270-278.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Nam Young Lee, Se Hyun Kim, Seong Jin Cho, Young-Cho Chung, In Kwa Jung, Chang Yoon Kim, Duk Ho Kim, Dong Geun Lee, Yo Han Lee, Weon Jeong Lim, Young Suk Na, Sang Eun Shin, Jong-Min Woo, Jin Sang Yoon, Bo-Hyun Yoon, Yong Min Ahn & Yong Sik Kim. (2014) A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. International Clinical Psychopharmacology 29:5, pages 279-287.
Crossref
Crossref
Adriaan Cleton, Stefaan Rossenu, Herta Crauwels, Joris Berwaerts, David Hough, Srihari Gopal, Marielle Eerdekens, An Vandebosch, Bart Remmerie, Marc De Meulder & Clara M. Rosso Fernández. (2014) A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. The Journal of Clinical Pharmacology 54:9, pages 1048-1057.
Crossref
Crossref
Takefumi Suzuki, Hiroyuki Uchida, Hiroyoshi Takeuchi, Takashi Tsuboi, Jinichi Hirano & Masaru Mimura. (2014) A review on schizophrenia and relapse-a quest for user-friendly psychopharmacotherapy. Human Psychopharmacology: Clinical and Experimental 29:5, pages 414-426.
Crossref
Crossref
Holland C. Detke, Peter J. Weiden, Pierre-Michel Llorca, Moutaz Choukour, Susan B. Watson, Elizabeth Brunner & Haya Ascher-Svanum. (2014) Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine. Journal of Clinical Psychopharmacology 34:4, pages 426-434.
Crossref
Crossref
T. H. Andersen, D. Kappers, B. Sneider, P. Uggerby & J. Nielsen. (2013)
Involuntary treatment of schizophrenia patients 2004–2010 in
D
enmark
. Acta Psychiatrica Scandinavica 129:4, pages 312-319.
Crossref
Crossref
Emilio Sacchetti, Antonio Vita, Alberto Siracusano & Wolfgang FleischhackerAlex Hofer & Wolfgang Fleischhacker. 2014. Adherence to Antipsychotics in Schizophrenia. Adherence to Antipsychotics in Schizophrenia
85
97
.
Jonathan M. Meyer. (2013) Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectrums 18:s1, pages 55-68.
Crossref
Crossref
Srividya IyerNicola BanksMarc-André RoyPhil TibboRichard WilliamsRahul ManchandaPierre ChueAshok Malla. (2017) A Qualitative Study of Experiences with and Perceptions regarding Long-Acting Injectable Antipsychotics: Part II—Physician Perspectives. The Canadian Journal of Psychiatry 58:5_suppl, pages 23-29.
Crossref
Crossref
Srividya IyerNicola BanksMarc-André RoyPhil TibboRichard WilliamsRahul ManchandaPierre ChueAshok Malla. (2017) A Qualitative Study of Experiences with and Perceptions regarding Long-Acting Injectable Antipsychotics: Part I—Patient Perspectives. The Canadian Journal of Psychiatry 58:5_suppl, pages 14-22.
Crossref
Crossref
Hyun-Ghang Jeong & Moon-Soo Lee. (2013) Long-acting Injectable Antipsychotics in First-episode Schizophrenia. Clinical Psychopharmacology and Neuroscience 11:1, pages 1-6.
Crossref
Crossref
Fiore Lalla & Larry Arshoff. (2013) A Mental Health Initiative to Enhance Schizophrenia Treatment Efficacy. Healthcare Management Forum 26:1, pages 46-50.
Crossref
Crossref
MARY OLADEJO & SUSAN BEWLEY. (2012) ADHERENCE IN PREGNANCY: A SYSTEMATIC REVIEW OF THE LITERATURE. Fetal and Maternal Medicine Review 23:3-4, pages 201-229.
Crossref
Crossref
Feng Liang, Alvin V. Terry & Michael G. Bartlett. (2012) Determination of aripiprazole in rat plasma and brain using ultra‐performance liquid chromatography/electrospray ionization tandem mass spectrometry. Biomedical Chromatography 26:11, pages 1325-1332.
Crossref
Crossref
Alexandre Andrade Loch. (2012) Stigma and higher rates of psychiatric re-hospitalization: São Paulo public mental health system. Revista Brasileira de Psiquiatria 34:2, pages 185-192.
Crossref
Crossref
Alexandre Andrade Loch. (2012) Stigma and higher rates of psychiatric re-hospitalization: São Paulo public mental health system. Revista Brasileira de Psiquiatria 34:2, pages 185-192.
Crossref
Crossref
Natalie J. Carter. (2012) Extended-Release Intramuscular Paliperidone Palmitate. Drugs 72:8, pages 1137-1160.
Crossref
Crossref
Steve Kisely, Loys Ligate, Marc-André Roy & Terri Lavery. (2012) Applying Motivational Interviewing to the initiation of long-acting injectable atypical antipsychotics. Australasian Psychiatry 20:2, pages 138-142.
Crossref
Crossref
A. J. M. Brnabic, K. Kelin, H. Ascher-Svanum, W. Montgomery, Z. Kadziola & J. Karagianis. (2011) Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study. International Journal of Clinical Practice 65:9, pages 945-953.
Crossref
Crossref